Collagen Solutions has been acquired by RTI Surgical

England & Company is pleased to announce that it served as the exclusive financial advisor to Collagen Solutions, a premier global supplier, developer, and manufacturer of engineered biomaterial-based medical devices and components with applications in regenerative medicine, in its sale to RTI Surgical, a leading contract development and manufacturing organization (“CDMO”) in tissue engineering for regenerative medicine.

Company
Collagen Solutions Ltd.
Transaction
Sector
Activity
biomaterial medical device manufacturer
Date
Country
USA

RTI is a portfolio company of Montagu Private Equity, a leading Europe and U.S.-based private equity firm with $12 billion of assets under management.

“The England & Company team are experts in medical device marketing and contract manufacturing, with extensive relationships in the biomaterials and regenerative medicine spaces. They found us the ideal partner for this business and negotiated strong terms for us,” said Rick Mulford, CEO of Collagen Solutions.

Collagen Solutions provides its OEM customers with high-quality components and fully assembled devices made from medical-grade collagen and xenograft tissue. These devices are used in various therapeutic areas, including cardiovascular, wound care, orthopedics and sports medicine, dental, biosurgery, and neurosurgery. The Company is based in Eden Prairie, MN, and has additional strategically located manufacturing sites in the U.K., New Zealand, and Glencoe, MN.

RTI’s acquisition of Collagen Solutions will broaden RTI’s soft tissue portfolio by leveraging Collagen Solutions’ proficiency in bovine and porcine collagen materials. This transaction will also facilitate access to rapidly growing therapeutic fields, and it has the potential to expedite the creation of pioneering biomaterials with combination products and improve patient outcomes.

“Collagen Solutions is an excellent strategic fit for RTI Surgical, bringing specialized and complementary capabilities and expertise in soft tissue engineering,” said Olivier Visa, President and Chief Executive Officer, RTI Surgical.

Adrien Sassi, Partner at Montagu, added, “Supporting patient care by helping to bring clinically differentiated solutions to market in a fast and reliable way is at the core of RTI’s mission, and the acquisition of Collagen Solutions is a transformative step in this journey. It reinforces RTI’s ability to partner strategically with OEMs from early product development to full-scale commercialization, including in clinical applications facing unmet patient needs like structural heart and tissue reconstruction.”